ScienceGrail shares reportedly surged after FDA posted documents ahead of advisory meeting
STAT reports the cancer blood-test developer’s shares rose on September 21, 2026. Its coverage examines what a vote on the test could mean for patients, regulators and the company.
TLDR
Grail shares surged on September 21, 2026, after the FDA posted documents ahead of an advisory committee meeting, STAT reports. The company is developing a blood test for cancer. STAT’s coverage explores what a vote on the test could mean for Grail, patients and regulators.
Grail shares reportedly surged after FDA posted documents ahead of advisory meeting
STAT reports the cancer blood-test developer’s shares rose on September 21, 2026. Its coverage examines what a vote on the test could mean for patients, regulators and the company.